Inventiva (NASDAQ:IVA) Shares Gap Down – Time to Sell?

Posted by Geri Gentry on Jul 8th, 2026

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $4.56, but opened at $4.27. Inventiva shares last traded at $4.5040, with a volume of 487,692 shares changing hands.

Analysts Set New Price Targets

IVA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Truist Financial assumed coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $16.56.

Read Our Latest Stock Report on IVA

Inventiva Price Performance

The company’s 50-day moving average price is $4.48 and its 200-day moving average price is $5.32.

Institutional Investors Weigh In On Inventiva

Several institutional investors have recently bought and sold shares of the company. Creative Planning acquired a new position in shares of Inventiva during the second quarter valued at approximately $32,000. Virtu Financial LLC purchased a new stake in Inventiva in the 4th quarter valued at $60,000. XTX Topco Ltd purchased a new position in Inventiva during the fourth quarter worth about $84,000. Cerity Partners LLC purchased a new stake in shares of Inventiva during the 4th quarter valued at approximately $93,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Inventiva in the 3rd quarter valued at $116,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

(Get Free Report)

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.